文献速递骨软组织肉瘤与黑色素瘤

英国晚期及已切除黑色素瘤帕博利珠单抗三周与六周给药方案的处方实践比较

Comparison of three-weekly and six-weekly pembrolizumab United Kingdom prescribing practice for advanced and resected melanoma.
PubMed 文献 · Eur J Cancer · 2023-09-17

该多中心回顾性研究比较了英国8个中心277例黑色素瘤患者帕博利珠单抗三周(Q3W)与六周(Q6W)给药的疗效与安全性。结果显示两组≥3级不良事件发生率相似,12个月无复发生存率和无进展生存率均无显著差异,Q6W可作为合适的给药选择以减轻医疗资源负担。

要点

  • Q6W与Q3W的≥3级不良事件发生率相似(14.9% vs 15.5%)。
  • 辅助治疗患者12个月无复发生存率Q6W 78.9% vs Q3W 74.2%(HR 0.93)。
  • 晚期患者12个月无进展生存率Q6W 41.8% vs Q3W 55.9%(HR 1.21)。

核心结论

  • Q6W是帕博利珠单抗给药的合适选择,可减少医疗服务资源负担。

研究设计与样本

  • 回顾性多中心研究,纳入2019年4月至2020年8月英国8个中心接受帕博利珠单抗治疗的277例黑色素瘤患者,其中116例起始Q3W、161例起始Q6W。
  • 比较Q3W与Q6W队列的预设基线特征、毒性及疗效结局,并对处方医生进行处方实践调查。

主要发现

  • Q6W处方比例在各中心间存在差异(范围32-88%)。
  • 合并自身免疫性疾病(OR 0.33;95%CI 0.12-0.82)和晚期疾病(相对于已切除疾病,OR 0.54;95%CI 0.33-0.90)与接受Q3W而非Q6W的可能性增加相关。
  • Q6W与Q3W的毒性结局大致相似:≥3级不良事件发生率分别为14.9%与15.5%。
  • 辅助治疗患者估计12个月无复发生存率Q6W为78.9%,Q3W为74.2%(HR 0.93;95%CI 0.50-1.73)。
  • 晚期患者估计12个月无进展生存率Q6W为41.8%,Q3W为55.9%(HR 1.21;95%CI 0.67-2.18)。

关键数值与推荐

  • Q6W与Q3W的≥3级不良事件发生率分别为14.9%与15.5%。
  • 辅助治疗12个月无复发生存率Q6W 78.9% vs Q3W 74.2%(HR 0.93;95%CI 0.50-1.73)。
  • 晚期患者12个月无进展生存率Q6W 41.8% vs Q3W 55.9%(HR 1.21;95%CI 0.67-2.18)。

临床怎么用

  • Q6W是帕博利珠单抗给药的合适选择,可减少医疗服务资源负担。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pembrolizumab is approved for the treatment of advanced and resected melanoma and was originally licensed as a three-weekly infusion (Q3W). In April 2019, a six-weekly infusion schedule (Q6W) was also approved. We retrospectively reviewed pembrolizumab prescribing for patients with melanoma across multiple United Kingdom (UK) centres to compare the safety and efficacy of Q6W with Q3W in real-world clinical practice. METHODS: Case notes for melanoma patients treated with pembrolizumab between April 2019 and August 2020 at eight UK centres were reviewed. Prespecified baseline characteristics of the Q3W and Q6W cohorts were compared, as well as toxicity and efficacy outcomes. Prescribers were surveyed about their prescribing practice. RESULTS: Two hundred seventy-seven patients were included: 116 commenced Q3W and 161 commenced Q6W pembrolizumab. The proportion of Q6W prescriptions varied by the centre (range 32-88%). Patient factors associated with an increased likelihood of receiving Q3W over Q6W were preexisting autoimmune comorbidity (odds ratio [OR] 0.33; 95% confidence interval [CI] 0.12-0.82) and treatment for advanced (versus resected) disease (OR 0.54; 95%CI 0.33-0.90). Toxicity outcomes were broadly similar for Q6W and Q3W: 14.9% versus 15.5% ≥ grade 3 Common Terminology Criteria for Adverse Events. Estimated 12-month recurrence-free survival for adjuvantly treated patients was 78.9% for Q6W and 74.2% for Q3W (hazard ratio [HR] 0.93; 95%CI 0.50-1.73). Estimated 12-month progression-free survival for advanced patients was 41.8% for Q6W and 55.9% for Q3W (HR 1.21, 95%CI 0.67-2.18). CONCLUSIONS: Q6W is an appropriate option for administering pembrolizumab, given the opportunity to reduce the health service resource burden.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Mehta I, Dayimu A, Kumar S, et al. Comparison of three-weekly and six-weekly pembrolizumab United Kingdom prescribing practice for advanced and resected melanoma. Eur J Cancer. 2023. PMID: 37804771. doi:10.1016/j.ejca.2023.113344

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。